floatz

floatz is an AI-driven platform designed for biotech and life-science investors to conduct rigorous scientific due diligence. Its core purpose is to uncover hidden scientific risks that conventional analysis often misses, enabling capital commitments to be made only after a thorough evaluation of the underlying science. The platform operates on a knowledge graph that integrates scientific publications, clinical trial data, intellectual property, and investigator profiles into a single interconnected evidence system. Instead of assessing isolated claims, floatz evaluates each piece of evidence in the full context of related research, prior results, and peer-reviewed literature. This allows it to surface contradictions, weak correlations, implicit assumptions, and gaps in evidence that human analysts might overlook. For example, when reviewing a therapeutic candidate, floatz can cross-reference its mechanism of action against existing studies, identify whether negative results from similar molecules have been suppressed, and check if the same team has previously published conflicting data. It also analyzes patent landscapes to determine whether claims are novel or merely incremental, and examines trial designs for potential biases. The platform provides structured reports that highlight areas of scientific uncertainty, such as missing control arms, small sample sizes, or ambiguous endpoints. Investors can use these insights to prioritize which assets require deeper manual review and which carry unacceptable risk. floatz is particularly useful for early-stage venture capital firms, family offices, and corporate development teams that need to evaluate dozens of candidates quickly while maintaining high standards of evidence. The system supports longitudinal tracking of scie